Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24,09:00-12:10
Innovative Small Molecule Chemical Drugs Session
Stay tuned
09:00-09:20 Data-Driven Insights into Global Trends in Small Molecule Drug Discovery
Li Tianquan:Founder & Vice President ofYaozhi.com
09:20-09:35 Emerging Trends in Small Molecule Drug Discovery: From Target Selection to Pipeline Strategy
Wang Kuifeng:Founder & CEO, GenHouse Bio
09:35-09:50 Haisco's Innovation Strategy for Novel Drug Discovery
Yan Pangke:General Manager, Haisco Pharmaceutical Group
09:50-10:05 Structural Biology Enabling Proximity-Based Drug Discovery
Jiaquan Wu:Biortus SVP
10:05-10:20 Automation Strategies in Drug Discovery
JI NIE:Senior Product Manager, Beckman Coulter Life Sciences
10:20-10:35 Not All JAKi’s are Created Equal
Wan Zhaokui:Chairman of Board & CEO, Lynk Pharmaceuticals
10:35-10:50 Trends in the application of Spray Drying for Small Molecule Drug Development
David Brugat Plata:Production Manager,ESTEVE
10:50-11:05 TSN1611: Tyligand's Selective KRAS G12D Inhibitor
Tony Zhang:Founder & CEO, Tyligand Bioscience
11:05-11:20 Mechanism-Driven Innovation: Fourth-Generation BTK Inhibitor Lorbretinib for Overcoming B-Cell Lymphoma Resistance
Yi Chen:Co-founder, Lupeng Pharmaceuticals
11:20-11:35 From Single Targets to Multi-System Modulation: Salubris' Strategy for CKM Syndrome Drug Development
Mu Shengmei:CMO, Salubris Pharmaceuticals
11:35-11:50 Innovative Drug Development for Chronic Hepatitis B
George Zhang:Chairman, Akeylink Biotechnology
11:50-12:10 FIC/BIC Drug Discovery Based on Validated Targets
Deng Haibing:head of medicinal chemistry, Abbisko